$218 Million is the total value of Stonepine Capital Management, LLC's 23 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
SCYX | Exit | SCYNEXIS INC | $0 | – | -6,327 | -100.0% | -0.02% | – |
SPNE | Exit | SEASPINE HOLDINGS CORP | $0 | – | -8,349 | -100.0% | -0.06% | – |
CFRX | Exit | CONTRAFECT CORP | $0 | – | -34,413 | -100.0% | -0.06% | – |
IMUX | Exit | IMMUNIC INC | $0 | – | -22,409 | -100.0% | -0.09% | – |
NBSE | Exit | NEUBASE THERAPEUTICS INC | $0 | – | -109,742 | -100.0% | -0.18% | – |
EYPT | Exit | EYEPOINT PHARMACEUTICALS INC | $0 | – | -80,537 | -100.0% | -0.38% | – |
LPTX | Exit | LEAP THERAPEUTICS INC | $0 | – | -250,000 | -100.0% | -0.46% | – |
ANGN | Exit | ANGION BIOMEDICA CORP | $0 | – | -280,183 | -100.0% | -1.24% | – |
KALV | Exit | KALVISTA PHARMACEUTICALS INC | $0 | – | -200,000 | -100.0% | -1.59% | – |
YMTX | Exit | YUMANITY THERAPEUTICS INC | $0 | – | -481,692 | -100.0% | -2.26% | – |
GMDA | Exit | GAMIDA CELL LTD | $0 | – | -1,724,201 | -100.0% | -3.08% | – |
AFMD | Exit | AFFIMED NV | $0 | – | -1,161,466 | -100.0% | -3.27% | – |
SBBP | Exit | STRONGBRIDGE BIOPHARMA PLC | $0 | – | -4,489,687 | -100.0% | -4.17% | – |
CBIO | Exit | CATALYST BIOSCIENCES INC | $0 | – | -2,635,014 | -100.0% | -4.93% | – |
GLPG | Exit | GALAPAGOS NV-SPON ADRspons adr | $0 | – | -244,205 | -100.0% | -5.85% | – |
ADMS | Exit | ADAMAS PHARMACEUTICALS INC | $0 | – | -3,914,938 | -100.0% | -8.75% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
XOMA CORP | 20 | Q3 2023 | 5.7% |
Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
AFFIMED NV | 13 | Q3 2022 | 7.7% |
ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13G | 2024-04-19 |
13F-HR | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.